Company Overview - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing novel biologics for inflammatory and immune (I&I) markets, including treatments for Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [3] - The company's lead program, Zumilokibart (APG777), is being developed primarily for AD, which is identified as the largest and least penetrated market within I&I [3] - Apogee aims to achieve best-in-class efficacy and dosing through its antibody programs, which target established mechanisms of action and utilize advanced antibody engineering [3] Upcoming Events - Management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 a.m. E.T. [1] - The company will also attend the UBS Biotech Summit Miami on March 9, 2026, and the Jefferies Biotech on the Beach Summit on March 10, 2026 [1] Investor Relations - For investor inquiries, Noel Kurdi serves as the VP of Investor Relations at Apogee Therapeutics [4] - Media inquiries can be directed to Dan Budwick at 1AB [4]

Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immune (I&I) markets, including treatments for Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [2] - The company's lead program, Zumilokibart (APG777), is primarily aimed at treating AD, which is identified as the largest and least penetrated market within I&I [2] - Apogee's antibody programs are designed to enhance efficacy and dosing by targeting established mechanisms of action and utilizing advanced antibody engineering to improve properties such as half-life [2] Upcoming Events - Management of Apogee Therapeutics will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 p.m. E.T. [1] - A live and archived webcast of the event will be accessible on the company's website under the Investors section [1]

Title text 2 Zumilokibart (APG777) Asthma Phase 1b Interim Results January 6, 2026 Disclaimers and Forward-looking Statements This presentation contains certain "forward-looking statements" within the meaning of applicable securities laws. Other than statements of historical facts, all statements included in this presentation are forward-looking statements, including statements about the potential for zumilokibart (APG777) in asthma; Apogee's plans for its current and future product candidates and programs; ...